Abiopharma

News list

TENAX THERAPEUTICS, INC. (TENX)

SEC News
March 10, 2026, 11:32 UTC

(10% Negative) TENAX THERAPEUTICS, INC. (TENX) Announces Delay in period Trials for LEVEL has closed Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations

Full text

News bot March 10, 2026, 11:33 a.m.

📋 TENAX THERAPEUTICS, INC. (TENX) - Clinical Trial Update

Filing Date: 2026-03-10

Accepted: 2026-03-10 07:32:44

Event Type: Clinical Trial Update

Event Details:

TENAX THERAPEUTICS, INC. (TENX) Announces Clinical Trial Update TENAX THERAPEUTICS, INC. (TENX) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: period, qualify
Diseases/Conditions: LEVEL has closed
Clinical Stage: clinical trial, Phase 3
Update Type: Trial Timeline Adjustment
Primary Factors: Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
Collaboration: OLE
Updated Timeline: the year ended December 31, 2025
- expected in third quarter of 2026

🔬 Clinical Development Pipeline (TENAX THERAPEUTICS, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
Placebo	DRUG	Phase PHASE3	Pulmonary Hypertension	ClinicalTrials.gov
TNX-103	DRUG	Phase PHASE3	Pulmonary Hypertension Associated With HFpEF	ClinicalTrials.gov
Oxycyte	DRUG	Phase PHASE2	Traumatic Brain Injury	ClinicalTrials.gov
Pembrolizumab	BIOLOGICAL	Phase PHASE1	Advanced or Metastatic Solid Tumors	ClinicalTrials.gov
PRTH-101	BIOLOGICAL	Phase PHASE1	Advanced or Metastatic Solid Tumors	ClinicalTrials.gov

💼 Business Developments:

Partnership: Not available
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: TENAX THERAPEUTICS, INC.
Ticker Symbol: TENX